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Abstract
Multiple studies have demonstrated an association between cigarette smoking
and increased anxiety symptoms or disorders, with early life exposures potentially
predisposing to enhanced anxiety responses in later life. Explanatory models sup-
port a potential role for neurotransmitter systems, inflammation, oxidative and
nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis,
and epigenetic effects, in anxiety pathogenesis. All of these pathways are affected
by exposure to cigarette smoke components, including nicotine and free radicals.
This review critically examines and summarizes the literature exploring the role
of these systems in increased anxiety and how exposure to cigarette smoke may
contribute to this pathology at a biological level. Further, this review explores the
effects of cigarette smoke on normal neurodevelopment and anxiety control, sug-
gesting how exposure in early life (prenatal, infancy, and adolescence) may pre-
dispose to higher anxiety in later life. A large heterogenous literature was
reviewed that detailed the association between cigarette smoking and anxiety
symptoms and disorders with structural brain changes, inflammation, and cell-
mediated immune markers, markers of oxidative and nitrosative stress, mito-
chondrial function, neurotransmitter systems, neurotrophins and neurogenesis.
Some preliminary data were found for potential epigenetic effects. The literature
provides some support for a potential interaction between cigarette smoking,
anxiety symptoms and disorders, and the above pathways; however, limitations
exist particularly in delineating causative effects. The literature also provides
insight into potential effects of cigarette smoke, in particular nicotine, on neuro-
development. The potential treatment implications of these findings are discussed
in regards to future therapeutic targets for anxiety. The aforementioned pathways
may help mediate increased anxiety seen in people who smoke. Further research
into the specific actions of nicotine and other cigarette components on these
pathways, and how these pathways interact, may provide insights that lead to
new treatment for anxiety and a greater understanding of anxiety pathogenesis.
Introduction
Cigarette smoking is the single biggest contributor to
death and morbidity worldwide (Gellert et al. 2012).
Smoking rates are significantly higher in anxiety-
disordered populations (Lasser et al. 2000; Tobias et al.
2008; Lawrence et al. 2010), and numerous studies support
a relationship between cigarette smoking and psychiatric
disorders (see review Dome et al. 2010). Three nonmu-
tually exclusive models may explain the smoking–anxiety
association (Moylan et al. 2012a). First, smoking may lead
to increased anxiety; second, anxiety may increase smoking
rates; or third, smoking and anxiety rates may both be
influenced by shared vulnerability factor(s).
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Evidence suggests that individuals with increased anxiety
are more likely to smoke (Brown et al. 1996; Patton et al.
1998; Sonntag et al. 2000; Goodwin et al. 2005; Cuijpers
et al. 2007; Swendsen et al. 2010). Multiple factors have
been proposed to explain this, including use of cigarettes to
reduce anxiety (i.e., self-treatment) and an increased sus-
ceptibility of those with anxiety in initiating smoking in
response to peer pressure (Patton et al. 1998; Tjora et al.
2011). In addition, smoking appears to increase the risk of
developing increased anxiety (Breslau and Klein 1999;
Johnson et al. 2000; Isensee et al. 2003; Goodwin et al.
2005; Cuijpers et al. 2007; Pedersen and von Soest 2009).
Potential explanatory models for this include the effects of
smoking on neurotransmitters, neurobiology, respiratory
health and autonomic control (Klein 1993; Niedermaier
et al. 1993; Zvolensky et al. 2003; Zvolensky and Bernstein
2005; Preter and Klein 2008), in addition to effects on nor-
mal neurodevelopmental (Dwyer et al. 2008; Iniguez et al.
2009). Finally, numerous shared vulnerability factors have
been identified that may increase the likelihood of both
smoking and increased anxiety (Reichborn-Kjennerud
et al. 2004; Hettema et al. 2005). For example, lower socio-
economic status is associated with both increased smoking
behaviors (Schaap and Kunst 2009; Tjora et al. 2011) and
anxiety (Kessler et al. 2005).
Despite the significant health impacts arising from the
comorbidity between smoking and anxiety, the biological
mechanisms underpinning this association have received
less investigation than for other psychiatric disorders. The
relationship between smoking and anxiety is complex as
evidence supports that cigarette smoke can reduce anxiety
in some smokers (see review Morissette et al. 2007). In
addition, smokers often report increased anxiety post
smoking cessation, although recent data conflict with this
finding (Bolam et al. 2011; McDermott et al. 2013). There
is also significant heritability in both anxiety expression
and smoking behaviors.
Recent advances in understanding the etiology of mood
and anxiety disorders support a key role for neurotransmit-
ter systems, the immune system, oxidative and nitrogen
stress (O&NS), mitochondrial dysfunction, neurotrophins
(NTs) and neurogenesis, and epigenetic effects in patho-
genesis (Berk et al. 2011; Moylan et al. 2012b). All of these
systems are affected by exposure to cigarette smoke.
This review critically examines and summarizes the
literature that has explored how cigarette smoking may
increase the likelihood of developing increased anxiety
and anxiety disorders. In this review, we focus on rele-
vant biological mechanisms (e.g., neurotransmitter sys-
tems, inflammation, oxidative and nitrosative stress,
mitochondrial dysfunction, dysregulation of NTs and
neurogenesis, and epigenetic effects) that potentially
mediate how smoking may influence anxiety symptoms.
Extensive literature has explored numerous psychological
and social contributors to a relationship between anxiety
and cigarette smoking. Readers interested in these path-
ways should consult the numerous excellent reviews
available (Zvolensky et al. 2005; Morissette et al. 2007;
Ameringer and Leventhal 2010). These reviews also con-
tain discussions regarding anxiety definition and symp-
tom structures of different anxiety disorders. Our aim
with the discussion of these specific pathways was to
provide a framework for future research that can be
integrated with other theories of anxiety development,
to hopefully lead to a holistic understanding of anxiety
pathogenesis.
Methods
For this narrative review, we searched biomedical databases
PubMed, Embase, and PsycInfo in mid-2012 using terms
“anxiety”, “anxiety disorder”, “panic disorder”, “post trau-
matic stress disorder”, “obsessive compulsive disorder”,
“generalized anxiety disorder”, “social phobia”, “inflamma-
tion”, “immune”, “tobacco”, “cigarette”, “smoke”, “nico-
tine”, “oxidative stress”, “nitrogen stress”, “mitochondria”,
“neurotrophin”, “neurogenesis”, and “psychiatry” in vari-
ous combinations to identify relevant papers for the out-
lined sections. We did not limit the search by year of
publication, but did limit to English language publications.
We were deliberately inclusive in identifying relevant
papers due to the scant availability of research in some
areas. All bibliographies of identified papers were searched
for further relevant information. Once acquired, studies
were grouped into the following headings: clinical studies,
structural brain changes and clinical correlates, neurotrans-
mitter systems, inflammation and cell-mediated immune
activation, oxidative and nitrosative stress, mitochondrial
function, NTs and neurogenesis, epigenetics and neurode-
velopmental effects.
Where possible, we presented literature pertaining to
individual anxiety disorder states (e.g., panic disorder
[PD], post traumatic stress disorder [PTSD], generalized
anxiety disorder [GAD] etc.). Where this was not possible
(e.g., in discussion of studies pertaining to psychological
stress or anxiety symptom scores, or in animal studies),
we have presented results relating to “anxiety” in general.
Clinical Studies
Cigarette smoking as risk factor for anxiety
disorders – epidemiological studies
In addition to many studies demonstrating a cross-
sectional relationship between cigarette smoking and anxi-
ety disorders, numerous population-based studies (Breslau
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and Klein 1999; Johnson et al. 2000; Isensee et al. 2003;
Goodwin et al. 2005; Cuijpers et al. 2007; Chou et al.
2011) have demonstrated smoking as being prospectively
associated with increased rates of anxiety disorders (see
review Moylan et al. 2012a). Although most have utilized
adult populations, some studies have demonstrated ado-
lescent smoking as being associated with increased rates of
some anxiety disorders (Johnson et al. 2000; Goodwin
et al. 2005). For example, in a study utilizing data from
the Oregon Adolescent Depression Project, the odds ratio
of expressing PD at age 24 when comparing baseline (age
14–18) daily smoking to nondaily smoking was 5.1 (95%
CI 2.4–10.5), which remained significant after controlling
for other anxiety disorders and parental risk factors.
Similarly, increased odds of numerous adult anxiety disor-
ders (GAD: OR 5.53 [1.84–16.66] and PD: OR 15.58
[2.31–105.14]) and all anxiety disorders when grouped
(OR 10.78 [1.48–78.55]) was discovered for baseline
(age 14) heavy smokers (20+ cigarettes day) versus non-
heavy smokers (1–19 cigarettes daily) in adolescence
(Johnson et al. 2000). Breslau and Klein (1999) also dem-
onstrated smoking as increasing the risk of first onset of
both PD and panic attacks. In addition, nicotine depen-
dence has been associated with increased odds of anxiety
disorders (OR: 2.2 for men, 2.6 for women) (Breslau et al.
1991).
Laboratory/Biological Studies
Structural brain changes and clinical
correlates
Cigarette smoking and anxiety disorders are both associ-
ated with structural brain changes. Cigarette smoking has
been associated with diverse changes, including reduction
in integrity of cerebral white matter microstructure (Gons
et al. 2011), reduced prefrontal cortices (PFC) gray matter
volumes (Brody et al. 2004; Zhang et al. 2011a), reduced
gray matter volume or density in the anterior and posterior
cingulate gyri (Brody et al. 2004; Gallinat et al. 2006), and
reduced volume of frontal and temporal cortices and cere-
bellum (Gallinat et al. 2006) which may be consequence of
direct toxic or adaptive effects. Importantly, these changes
appear correlated with magnitude of cigarette exposure.
For example, the measured volumes of frontal lobes, tem-
poral lobes, and the cerebellum of smokers are inversely
correlated with magnitude of life exposure to tobacco
smoke, measured in pack years (P = 0.001) (Gallinat et al.
2006). In addition, pack years of smoking is inversely corre-
lated with density of PFC gray matter (Brody et al. 2004).
These changes overlap to some degree with neuroimaging
changes observed in mood and anxiety disorders (Moylan
et al. 2012b). Correlates of these structural changes may be
associated with cognitive deficits as consequence of ciga-
rette smoking (Durazzo et al. 2010), which have been
repeatedly demonstrated in smoking populations (Richards
et al. 2003; Nooyens et al. 2008; Peters et al. 2008; Sabia
et al. 2012). For example, smoking is associated with
reduced cognitive performance, and cognitive performance
improves with increasing time since smoking cessation
(Gons et al. 2011).
Individuals with anxiety disorders exhibit structural
brain changes potentially resulting from illness related or
secondary effects, although investigation in this area is still
evolving (Damsa et al. 2009). Many studies have demon-
strated the essential role of the amygdala, anterior insula,
and anterior cingulate cortex in the key processing of fear
conditioning and extinction, and potential role of the PFC
structures as possible moderators of amygdala fear
responses during extinction (Holzschneider and Mulert
2011). Studies have identified volumetric brain changes in
patients with PD (Asami et al. 2008, 2009; Hayano et al.
2009), including reduction in the anterior cingulate cortex
(Johnson et al. 2000; Asami et al. 2008), right ventromedial
cortex and amygdala, bilateral insular cortex, occipito-
temporal gyrus (Pedersen and von Soest 2009) and lateral
temporal cortex (van Tol et al. 2010). In patients with
GAD, volumetric assessment has produced inconsistent
results including increased (De Bellis et al. 2000; Schienle
et al. 2011) and decreased amygdala (Milham et al. 2005)
volumes and alterations to the PFC (Schienle et al. 2011),
which possibly relates to heterogeneity of samples used.
Lifetime GAD has also been associated with reduced hippo-
campal volumes, an effect independent of major depressive
disorder (Hettema et al. 2012). Functional studies have uti-
lized various symptom provocation models for specific
anxiety symptoms dependent upon the disorder being
studied. Besides results in obsessive–compulsive disorder
(OCD), where the predominant response is hyperactivity of
the anterior cingulate cortex (Deckersbach et al. 2006), the
majority of studies demonstrate hyperactivity of brain
regions associated with the fear response (amygdala), and
hypoactivity in areas thought to regulate the fear responses
(e.g., anterior cingulate cortex, PFC) (Holzschneider and
Mulert 2011).
Changes to white matter microstructure are present in
both smokers and individuals with anxiety disorders. Cig-
arette smoking appears to influence the integrity of white
matter (measured by change in fractional anisotropy
[FA]); however, variables such as age and nicotine depen-
dence appear to moderate this effect (Paul et al. 2008;
Gons et al. 2011). In available studies, cigarette smoking
is associated with increased measures of FA, although
levels of FA are negatively correlated with cigarette expo-
sure and nicotine dependence. For example, a study of
adults (33.7  7.9 years) by Hudkins et al. (2012)
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investigating white matter microstructure demonstrated
that smokers exhibited higher FA in multiple white mat-
ter regions than age-matched controls, but that the mag-
nitude of cigarette consumption and nicotine dependence
was negatively correlated with FA. Higher FA in smokers
was also shown in other studies (Jacobsen et al. 2007;
Paul et al. 2008), although FA increased with lower levels
of cigarette exposure (Paul et al. 2008). In a further
study, levels of FA were lower in smokers than non-
smokers (Berk et al. 2011). Attempting to resolve these
conflicting results, Hudkins et al. (2012) hypothesized
that FA could be increased in smokers, particularly in
adolescent smokers, due to the direct effects of nicotine
stimulating glial proliferation and activity (Paul et al.
2008; Hudkins et al. 2012). This effect would be more
pronounced in adolescence, as white matter proliferation
is faster in adolescence than adulthood. As exposure to
cigarette smoking continues through adult life, FA would
decrease faster in smokers than nonsmokers, secondary to
potential toxic effects of cigarette smoke, leading to lower
FA overtime (Hudkins et al. 2012). Similar to findings in
smoking, a number of studies have demonstrated altered
white matter structural integrity across various anxiety
disorders (for review see Ayling et al. 2012). For example,
patients with PD demonstrated higher FA values in the
left anterior and right posterior cingulate correlated with
symptom severity (Han et al. 2008). Further, studies in
patients with GAD demonstrated reduced FA in the unci-
nate fasciculus (Hettema et al. 2012) (connecting the
amygdala and orbitofrontal cortex), a result also demon-
strated in social phobia (SP) (Phan et al. 2009; Baur et al.
2011), and increased FA in the right postcentral gyrus
(Zhang et al. 2011b). In PTSD, lowered FA has been
found in areas including the left frontal gyrus, internal
capsule, and midbrain (Kim et al. 2005; Schuff et al.
2011). Changes in integrity of white matter pathways con-
necting fear areas, including the uncinate fasciculus and
corpus callosum, have been associated with trait anxiety
states (Kim and Whalen 2009; Baur et al. 2011; Westlye
et al. 2011).
We are aware of only one study assessing the effect of
psychiatric disorders and smoking on white matter integ-
rity. Zhang et al. (2010a), assessing patients with schizo-
phrenia, demonstrated reductions in FA of the left
anterior thalamic radiation/anterior limb of the internal
capsule that were both independent and additive in
smokers and patients with schizophrenia, such that smok-
ers with schizophrenia had the largest reductions in FA.
No studies to our knowledge have yet been conducted in
patients with anxiety disorders.
In summary, gross and microstructural changes to key
brain regions and white matter tracts are present in
cigarette smokers and patients with anxiety disorders.
Changes to white matter microstructure in certain regions
connecting fear response areas have been associated with
trait anxiety states, and it is possible that cigarette smoke
could negatively affect these pathways. Future research into
these areas may provide important insights into anxiety
pathogenesis.
Neurotransmitter systems
The importance of specific neurotransmitter systems has
been extensively demonstrated in anxiety disorders, with
current first-line pharmacological therapies interacting
predominantly with the serotonergic, noradrenergic, can-
nabinoid, cholinergic, and dopaminergic systems. In addi-
tion, some of these agents are also effective in enhancing
smoking cessation (Jorenby et al. 1999), suggesting a
plausible biological interaction between these systems and
nicotine dependence. Many studies have demonstrated
that nicotine and cigarette smoke affect diverse neuro-
transmitter systems. However, how these may predispose
to increased anxiety is very complex, involving interaction
between systems and differing effects of cigarette compo-
nents.
Much scientific work has explored the influence of
nicotinic acetylcholine receptors (nAChRs) on brain func-
tion. The nAChRs are widely distributed throughout the
central nervous system (CNS), located within synapses
(pre and post synaptic), on cell bodies, dendrites, and
axons (Bertrand 2010). Cholinergic innervation is wide-
spread throughout the brain innervating nearly every neu-
ral zone. Many cholinergic projections do not terminate
at synapses, but rather nonsynaptically where they
contribute to diffuse volume transmission (Dani and
Bertrand 2007). This could be the case for most hippo-
campal and cortical projections (Descarries et al. 1997),
and would be similar to the action of other neurotrans-
mitters including serotonin, dopamine, and noradrenaline
(Vizi et al. 2010). What differentiates cholinergic trans-
mission from these other neurotransmitters is that move-
ment of acetylcholine (ACh) is via diffusion that is
limited by acetylcholinesterase hydrolysis and not a reup-
take pump (Dani and Bertrand 2007). Differently located
nAChRs appear to exert different effects. Unlike in the
periphery, where nAChR activation underpins fast neuro-
transmission at neuromuscular junctions, the role of fast
transmission appears limited centrally although recent
results suggest a possible role in hippocampal pyramidal
neurons (Grybko et al. 2011). Many studies have identi-
fied a role for nAChRs in modulating neurotransmitter
concentrations, with activation of presynaptic nAChRs
known to enhance release of neurotransmitters acetyl-
choline, dopamine, noradrenaline, serotonin, glutamate,
and gamma-aminobutyric acid (GABA) (Dani and
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Bertrand 2007). This appears to be consequence of facili-
tating increasing concentration of intracellular Ca2+
through augmenting calcium influx and altering activity
of voltage-gated Ca2+ channels within the terminal. Alter-
ations in multiple receptor regulated intracellular Ca2+
pathways are linked to mood and anxiety disorders (Plein
and Berk 1999, 2001; Berk et al. 2001).
Numerous investigations have explored how activation
of nAChRs by nicotine can exert effects on mood and
anxiety symptoms. Nicotine can lead to both anxiogenic
and anxiolytic effects that appear to depend upon the
animal strain, dosing regimen, and experimental para-
digm utilized. Exposure to nicotine in rat models leads to
upregulation of nAChRs (Slotkin 2004) that is shortly fol-
lowed by desensitization as exposure is continued. Activa-
tion of nAChRs, particularly the a4b2 and a7 subtypes,
appears to enhance release of serotonin in several brain
regions, including the dorsal raphe nucleus (Reuben and
Clarke 2000; Ma et al. 2005). Interestingly, a4b2 receptor
knockout mice demonstrate an increase in basal anxiety
(Ross et al. 2000), suggesting a role for these receptors in
anxiety regulation. These receptors also upregulate dopa-
mine and noradrenergic neurons (Lichtensteiger et al.
1988), with these effects likely important in mediating the
anxiolytic effects of nicotine (McGranahan et al. 2011).
Data from a human study demonstrated that cigarette
smoking upregulated dopamine release from the limbic
system, a finding that correlated with improvement in
mood and anxiety symptoms, although the improvement
in anxiety symptoms didn’t appear dependent upon nico-
tine (Brody et al. 2009). Acute activation of nAChRs by
nicotine appears to produce anxiolytic effects in mouse
models that can be blocked by nAChR antagonist meca-
mylamine. In addition, nicotine appeared to attenuate
expression of c-Fos in numerous brain areas normally
upregulated during stress, including the paraventricular
hypothalamic nucleus, lateral hypothalamus, central
amygdaloid nucleus, medial amygdaloid nucleus and
cingulate and retrosplenial cortices (Hsu et al. 2007). In
one controlled study conducted in humans, administra-
tion of nicotine also improved mood in nonsmokers with
major depression (McClernon et al. 2006). In contrast to
these findings, acute administration of nicotine into the
lateral septum of rats precipitated an anxiogenic effect
that was at least partially mediated by serotonin 1A recep-
tors (Cheeta et al. 2000). Enhanced anxiety is a known
initial side effect to the early administration of selective
serotonin reuptake inhibitors (SSRIs) (Spigset 1999), a
time of significantly increased serotonergic transmission.
It is possible that enhanced release of serotonin via
nAChR activation may partially explain nicotine’s anxio-
genic effects in some circumstances. It should be noted,
however, that acute effects of nicotine generally appear to
differ from chronic effects, with homeostatic adaptations
potentially underpinning longer term effects.
In this context, the above results suggesting an acute
anxiolytic effect of nicotine in animal models contrasts
sharply with knowledge that most available anti-
depressants are antagonists of nAChRs (Shytle et al. 2002)
and physostigmine, a potent acetylcholinesterase inhibitor,
produces increased depressive and anxiety symptoms
when administered (Janowsky et al. 1974). A further
observation that may help clarify these seemingly conflict-
ing effects is that of nicotine-induced nAChR desensitiza-
tion. Desensitization of nAChRs is a complex process that
occurs with normal cholinergic transmission and varies
with degree of transmission and receptor subtype (Dani
and Bertrand 2007). As nicotine enters the brain more
gradually and is cleared more slowly than endogenous
ACh, nicotine has the ability to induce more sustained
desensitization of nAChRs (DeBry and Tiffany 2008). In
this regard, exogenous nicotine can potentially exert a
more profound inhibition of nAChRs than endogenous
acetylcholine, leading to a potential decrease in release of
various neurotransmitters. To support this, desensitization
of nAChRs by low concentrations of nicotine lead to
reduced release of GABA and dopamine in mice brains
(Grady et al. 2012). These effects may underpin observa-
tions in human studies of depression, where nicotine and
other cigarette components altering neurotransmitter sys-
tem may partially explain development of depressed states
(Dome et al. 2010). For example, smoking has been asso-
ciated with impaired serotonin function as measured by
fenfluramine challenge and measurement of colony-
stimulating factor (CSF) levels of 5-hydroxyindoleacetic
acid (Malone et al. 2003). However, this mechanism is
likely more complex than a simple up- or downregulation
of neurotransmitter release and responses vary with dif-
ferent nAChR subtypes. For example, long-term potentia-
tion responses in the hippocampal CA1 region appear
differentially affected by a7- and b2-containing nAChRs
(Nakauchi and Sumikawa 2012). One factor that further
complicates interpretation of this research relates to nico-
tine withdrawal, which is anxiogenic in animal and
human studies (Picciotto et al. 2002). In this regard, anx-
iolytic effects of nicotine exposure may be secondary to
relief of withdrawal (Mueller et al. 1998).
As it currently stands, the best explanation for how
both agonism and antagonism of nAChRs may exert anti-
depressant and anxiolytic effects relates to desensitization.
Direct exposure to nicotine can facilitate rapid desensiti-
zation of nAChRs, such that an indirect antagonist effect
is rendered. This “functional antagonism” (Gentry and
Lukas 2002) may underpin the antidepressant and
anxiolytic effects of nicotine (Picciotto et al. 2008),
although further research into the various effects of differ-
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ent nAChR subtypes and their relative activation/desensi-
tization balance is required.
It is also important to consider how other components
of cigarette smoke influence neurotransmitter function.
Smoking exerts effects on monoamine oxidase (MAO)
expression, including downregulation of MAO-A and
MAO-B in the brain (Fowler et al. 1996a,b) as well as influ-
encing methylation of MAO promoter genes (Rendu et al.
2011). Free radicals, another highly concentrated compo-
nent of cigarette smoke, can stimulate production of cell-
mediated immune cytokines such as interferon-gamma
(IFN-c) (Nunes et al. 2012). These proinflammatory
cytokines can influence serotonin metabolism, by activating
indoleamine 2,3-dioxygenase to preferentially convert tryp-
tophan into tryptophan catabolites, including kynurenine
and quinolinic acid, in lieu of serotonin. This can precipi-
tate a relative deficit in both tryptophan and serotonin,
which has been, although not exclusively, associated with
increased depressive and anxiety symptoms (Argyropoulos
et al. 2004; Bell et al. 2005; Kulz et al. 2007).
Inflammation and cell-mediated immune
activation
Inflammation and activation of cell-mediated immune
functions appears to be associated with psychiatric disor-
ders (Dantzer et al. 2008; Miller et al. 2009; Wager-Smith
and Markou 2011; Moylan et al. 2012b). Stress-induced
inflammatory mediators may impair key brain processes
in the hippocampus and PFC, including neuronal and
synaptic plasticity, neurogenesis, long-term potentiation,
and regulation of NTs. These actions may form part of
anxiety disorder pathogenesis (for review see Hovatta
et al. 2010) similar to their role in major depressive disor-
der (for reviews see Maes et al. 2011a; Moylan et al.
2012b). Cigarette smoking promotes increased systemic
inflammation and cell-mediated immune reactivity, pro-
cesses thought key to the pathogenesis of chronic physical
disorders such as chronic obstructive pulmonary disease
(Bhalla et al. 2009; Nikota and Stampfli 2012) and ath-
erosclerosis (Ambrose and Barua 2004; Armani et al.
2009). These actions may also contribute to pathogenesis
of anxiety.
Numerous studies have investigated levels of inflamma-
tory mediators in anxiety disorders and increased anxiety
states (Wadee et al. 2001). The results are heterogeneous,
endorsing both increases and decreases in mediators. For
example, psychological stress has been associated with
increased production of proinflammatory cytokines
including tumor necrosis factor-alpha (TNF-a),
interleukin-6 (IL-6), interleukin-1 receptor antagonist
(IL-1Ra), and IFN-c, coupled with decreased production
of anti-inflammatory cytokines including interleukin-10
(IL-10) and interleukin-4 (IL-4), with higher anxiety
responses associated with significantly greater IFN-c
(Maes et al. 1998). In another study, clinically anxious
individuals with a Hospital Anxiety and Depression Scale
(HADS) score  8 demonstrated significantly higher
levels of IL-6 and lower levels of serum cortisol, but no
difference in C-reactive protein (CRP), compared with
nonanxious individuals after controlling for depression
and neuroticism (O’Donovan et al. 2010).
Others studies, however, have demonstrated an inverse
relationship between psychological stress and levels of
TNF-a (Chandrashekara et al. 2007). Studies in patients
with OCD also demonstrate varying (Brambilla et al.
1997; Monteleone et al. 1998; Denys et al. 2004; Konuk
et al. 2007) expression of plasma TNF-a, interleukin-
1-beta (IL-1b), and IL-6. The first cytokine study per-
formed in OCD found no increase in levels of interleu-
kin-1 (IL-1), IL-6, or soluble interleukin-2 receptor (sIL-
2R), although severity of compulsive symptoms was posi-
tively correlated with concentrations of plasma IL-6 and
interleukin-6 receptor (IL-6R) (Maes et al. 1994), suggest-
ing that IL-6 signaling may be associated with compulsive
behavior. In another study comparing OCD and general-
ized social anxiety disorder (GSAD), lipopolysaccharide-
induced production of IL-6 was decreased in OCD but
maintained in GSAD (Fluitman et al. 2010). Interestingly,
patients with OCD generally demonstrate lower rates of
smoking than in other anxiety disorders (Bejerot and
Humble 1999), with results also suggesting possible cho-
linergic supersensitivity in these disorders (Lucey et al.
1993).
Few studies have investigated inflammatory cytokines
levels (Marazziti et al. 1992; Brambilla et al. 1999) and
alterations of other immune cell markers (Rapaport
1998; Park et al. 2005) in PD, with data showing hetero-
geneous results. No significant changes in any of these
variables could be found during CO2 inhalation-induced
panic (van Duinen et al. 2008). Numerous investigations
support upregulated inflammatory activity in PTSD (for
review see Gill et al. 2009), including increased produc-
tion of IL-6 (Maes et al. 1999; Bob et al. 2010),
increased TNF-a, IFN-c, IL-1b, and decreased produc-
tion of interleukin-8 (IL-8) and interleukin-2 (IL-2).
More recently, increases in a number of proinflammato-
ry cytokines and chemokines (IL-6, IL-1a, IL-1b, IL-8,
monocyte chemotactic protein-1 [MCP-1], macrophage
inflammatory protein-1 a [MIP-1a], eotaxin, granulocyte
macrophage CSF [GM-CSF], interferon-alpha [IFN-a])
were observed in patients with PD and PTSD (Hoge
et al. 2009).
A number of factors may help explain the above heter-
ogeneous results, including differences between anxiety
disorder subtypes, study design, and confounding factors.
ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 307
S. Moylan et al. Smoking and Anxiety Symptoms and Disorder
Despite these heterogeneous results, other insights suggest
increased inflammation contributes to anxiety pathogene-
sis. For instance, cytokine-based immunotherapy can lead
to increased anxiety symptoms (Maes et al. 2001). Fur-
thermore, depressive and anxiety symptoms induced by
administration of cytokines are responsive to selective
SSRIs (Gupta et al. 2006; de Knegt et al. 2011).
We are not aware of any studies that have assessed
the impact of cigarette smoking on inflammatory medi-
ator expression in anxiety disorders. However, there is
evidence that smoking and depression act synergistically
to increase inflammation (Nunes et al. 2012). Further,
in a study assessing cytokine levels in the gingival cre-
vicular fluid in patients with periodontal disease, levels
of inflammatory cytokines IL-6 and IL-8 were both pos-
itively correlated with increasing psychological stress, as
measured by the Modified and Perceived Stress Scale
(Linn 1986), and cigarette smoking (Giannopoulou et al.
2003).
Oxidative and nitrosative stress
Free radicals are by-products of oxidative phosphorylation
that, at low or moderate concentrations, participate in
normal cellular processes such as signaling pathways,
mitosis, apoptosis, and responses to injury or infection
(Valko et al. 2007). However, damage can occur to cellu-
lar components, including proteins, nucleic acid, carbohy-
drates, and lipids when levels of oxidative free radicals
increase beyond the antioxidant capacity of cells. Increases
in free radical concentrations can occur through both
increased production of reactive oxygen species (ROS)
and reactive nitrogen species (RNS) and/or decreased
expression of antioxidants (Hovatta et al. 2010). Damage
to these cellular components can alter the structure and
function of membrane fatty acids and proteins, and alter
or damage DNA and mitochondrial function leading to
cell death (Maes et al. 2011b).
Increased plasma markers of O&NS have been repeat-
edly demonstrated in anxiety-disordered populations and
animal models of anxiety (for review see Hovatta et al.
2010). In addition, increased hippocampal oxidative stress
is anxiogenic (de Oliveira et al. 2007). For example,
plasma markers of increased lipid peroxidation (malondi-
aldehyde [MDA], thiobarbituric acid reactive substances
[TBARS]) have been demonstrated in OCD (Ersan et al.
2006; Chakraborty et al. 2009; Ozdemir et al. 2009), SP
(Atmaca et al. 2008), PD (Kuloglu et al. 2002), and PTSD
(Tezcan et al. 2003). Further, studies in populations with
anxiety disorders have demonstrated increased activity of
antioxidant enzymes superoxide dismutase (SOD), catalase
(CAT), xanthine oxidase, glutathione reductase (GSR),
and glutathione peroxidase (Kuloglu et al. 2002; Tezcan
et al. 2003; Herken et al. 2006; Atmaca et al. 2008; Ozd-
emir et al. 2009). Although these effects are not consistent
across all studies (Ozdemir et al. 2009; Hovatta et al.
2010), it suggests that increased levels in oxidative stress
do appear in anxiety-disordered populations. Psychological
stress appears to be associated with increased O&NS and
brain region specific O&NS induced cellular damage (Hov-
atta et al. 2010), as demonstrated by increased superoxide
production in the mitochondria of rat hippocampus and
PFC under chronic mild stress (Lucca et al. 2009), and
increased NO production in rat hippocampus (Harvey
et al. 2004) and in rat cortex (Olivenza et al. 2000) in a
stress–restress animal model. Psychological stress
(e.g., examination stress) is accompanied by an increase in
inflammatory markers, lipid peroxidation, oxidative dam-
age to DNA, and reduced antioxidant activity in the
plasma (Wadee et al. 2001; Sivonova et al. 2004).
Increased stress levels (e.g., increased perceived workload)
and the impossibility to cope with stress have been associ-
ated with elevated 8-hydroxydeoxyguanosine (8-OHdG)
levels (Irie et al. 2005).
ROS and RNS interact in a bidirectional fashion with
proinflammatory cytokine signaling pathways (Hovatta
et al. 2010) leading to enhanced O&NS. One example is of
neopterin, which is synthesized from macrophages after
stimulation by proinflammatory cytokines (IFN-c). Pro-
duction of neopterin increases production of NO through
upregulating inducible nitric oxide synthase (iNOS) gene
expression (Maes et al. 2012). Further, the proinflammato-
ry cytokines IL-1b and TNF-a increase superoxide produc-
tion by stimulating arachidonic acid release, leading to
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase activation (Chenevier-Gobeaux et al. 2007), and
activation of proinflammatory transcription factors,
including nuclear factor k b (NFkb) and the cyclic adeno-
sine monophosphate (cAMP) response element binding
(CREB) family, appear to regulate the production of
O&NS by modulating the activity of NOS, cyclooxygenase
2 (COX2), and NADPH oxidase (Hovatta et al. 2010).
Alterations in activity of these particular enzymes have also
been linked to anxiety behaviors. For example, enhanced
anxiety resulted from the downregulation of NOS through
administration of a NOS inhibitor in one study (Masood
et al. 2009). However, these results were not replicated in
another study, which demonstrated that downregulation of
NOS by stimulation of serotonin 1A receptors (5-HT1aR)
lead to an anxiolytic effect, mediated by an increase in
CREB phosphorylation resulting from decreased NO pro-
duction (Zhang et al. 2010b). Increased activation of CREB
in the nucleus accumbens is associated with increased neu-
ronal survival (Mantamadiotis et al. 2002) and has also
been associated with reduced anxiety (Barrot et al. 2005).
Inhibition of phosphodiesterase E2 (PDE2), which in turn
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inhibits activity of NADPH oxidase, reduces anxiety behav-
ior associated with induced oxidative stress (Masood et al.
2009). Increased hippocampal NADPH oxidase 1 activity
appeared to increase anxiety behavior in rats with adjuvant
arthritis (Skurlova et al. 2011).
Subchronic oxidative stress may mediate anxiety
responses through effects on NTs and enzymatic activity.
Subchronic oxidative stress appears to induce downregu-
lation of brain-derived neurotrophic factor (BDNF), gly-
oxalase 1 (GLO1), and GSR1 (Salim et al. 2011). BDNF is
a critical brain NT and also acts as a potential antioxidant
mediator (Lee and Son 2009; Chan et al. 2010). Local
increases in GLO1 and GSR1 enzyme expression, whose
functions include protection against dicarbonylglycation
and production of glycation end products (Hambsch
2011), have previously been associated with increased
anxiety-like behaviors (Hovatta et al. 2005). However,
Salim et al. (2011) demonstrated that subchronic oxida-
tive stress downregulates GLO1 and GSR1 via induction
of calpain expression in the hippocampus, predisposing
to increased protein glycation and subsequent further oxi-
dative stress. This increased oxidative stress, in concert
with calpain activation (Shumway et al. 1999), is pro-
posed to induce NFjB transcription, leading to enhanced
production of proinflammatory cytokines (IL-1, CRP,
TNF-a) and inflammatory-mediated cellular damage
(Salim et al. 2011). The induction of calpain mediated
decreased expression of BDNF (see section Neurotrophins
below) (Salim et al. 2011).
Cigarette smoke, a significant source of exogenous free
radicals (Stedman 1968), contains thousands of chemicals
that increase O&NS, and smokers or those exposed to pas-
sive smoke appear to have significantly reduced circulating
antioxidants (Sobczak et al. 2004; Swan and Lessov-Schlag-
gar 2007). Many studies have demonstrated changes con-
sistent with increased O&NS in the brains of animals
exposed to cigarette smoke. Such changes include increased
levels of ROS (Luchese et al. 2009) and RNS including
superoxide, TBARS, carbonylated proteins (Tuon et al.
2010), measures of lipid peroxidation (Anbarasi et al.
2005a; Stangherlin et al. 2009; Thome et al. 2011), and
reduction of antioxidant enzymes (Stangherlin et al. 2009)
including SOD (Luchese et al. 2009), catalase (Luchese
et al. 2009), glutathione peroxidase, GSR, glutathione, and
vitamins (A, C, E) (Anbarasi et al. 2006a). It should be
noted that there are some exceptions to this trend (Delibas
et al. 2003; Fuller et al. 2010). Although some studies
report an increase in these antioxidant enzymes after acute
exposure to cigarette smoke (Baskaran et al. 1999), this is
likely an adaptive response designed to protect against oxi-
dative damage (Hilbert and Mohsenin 1996). Over the
longer term, chronic cigarette exposure appears to over-
whelm these adaptive host antioxidant responses (Hulea
et al. 1995; Anbarasi et al. 2006a) leaving the system vul-
nerable to cellular damage. The importance of deteriora-
tion in antioxidant levels is underlined by the fact that
cigarette smoke-induced increases in markers of lipid per-
oxidation are prevented by vitamin E (Thome et al. 2011).
Furthermore, another study demonstrated that active exer-
cise reduced expression of oxidative stress produced sec-
ondary to cigarette smoke exposure in rats (Tuon et al.
2010). The ability of exercise to modulate oxidative stress
may also partially underpin its therapeutic effect on anxiety
disorders (Moylan et al. 2013).
Exogenous nicotine administration to isolated cell lines
in vitro reduces antioxidant constituents (e.g., glutathione)
and increases markers of lipid peroxidation (MDA) and
lactate dehydrogenase activity (Yildiz et al. 1998, 1999),
effects blocked by addition of detoxifying enzymes SOD
and CAT (Yildiz et al. 1998, 1999). Investigations into the
effects of nicotine on oxidative stress in CNS cells have been
more limited. In a study that utilized chronic nicotine
exposure administered for 10 days, results demonstrated
increased levels of TBARS and HNE (4-hydroxynonenal)
in the brain (Bhagwat et al. 1998). Cigarette smoke can
also increase levels of brain heat shock protein 70 kDa
(Anbarasi et al. 2006b).
Only one study to our knowledge has simultaneously
assessed the association between cigarette smoke exposure,
anxiety symptoms, and brain oxidative stress markers. In
this study, rats exposed to cigarette smoke showed
increased markers of brain lipid peroxidation and
decreased plasma ascorbic acid. When rats were addition-
ally treated with pecan nut shell extract, a substance with
antioxidant properties, improvements were demonstrated
in anxiety symptoms (interpreted as withdrawal symp-
toms) and markers of lipid peroxidation (Reckziegel et al.
2011).
Mitochondrial function
Mitochondria are important sources of oxidative stress
and many abnormalities in mitochondrial function have
been found in psychiatric disorders (for review see Manji
et al. 2012). Although still requiring much investigation,
multiple factors support a role for mitochondrial dysfunc-
tion in increasing anxiety. First, patients exhibiting mito-
chondrial disorders commonly demonstrate psychiatric
symptoms including increased anxiety (Miyaoka et al.
1997; Anglin et al. 2012). Second, recent investigations
have discovered decreased levels of glycolysis enzymes
coupled with increased expression of components
associated with the electron transport chain in high-
anxiety trait animal models, potentially increasing vulner-
ability to production of ROS and subsequent cellular
damage (Filiou et al. 2011). These results were coupled
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with observations of altered levels of proteins associated
with neurotransmission in high-anxiety mice thought to
be consequent to mitochondrial protein alteration (Filiou
et al. 2011). The authors hypothesize that mitochondria
may underpin a “unifying link between energy metabo-
lism, oxidative stress, and neurotransmission alterations”
that were observed between high- and low-anxiety trait
mice. Third, mitochondria-targeted antioxidant SkQ1 has
been associated with decreased expression of anxiety
behaviors in rats (Stefanova et al. 2010). Finally, mutant
mice with reduced function of Bcl-2, a key modulator of
mitochondrial function, demonstrate increased anxiety
behavior (Einat et al. 2005).
Exposure to cigarettes can lead to mitochondrial
dysfunction (Miro et al. 1999; Anbarasi et al. 2005b), as
demonstrated by increased levels of cholesterol, lipid per-
oxides and increased cholesterol/phospholipid ratio, in
conjunction with decreased mitochondrial enzymes in
those exposed to cigarette smoke. However, chronic
cigarette smoking was not associated with derangement of
mitochondrial function in a separate study, but did
prevent exercise-induced improvement in mitochondrial
function (Speck et al. 2011). A potential explanation for
absence of demonstrable mitochondrial dysfunction in
this study may relate to the use of SWISS mice in the
experimental design that were demonstrated to be highly
resistant to cigarette smoke-induced oxidative stress
(Rueff-Barroso et al. 2010). Recent evidence suggests that
nicotine exposure may worsen mitochondrial function
through direct effects on membrane potential and granu-
larity of desensitizing a7 nAChRs (Gergalova and Skok
2011). Given these preliminary results, investigation of
therapies that promote mitochondrial function in patients
with anxiety disorders would be fruitful. These studies
should take in account smoking status.
Neurotrophins and neurogenesis
Increasing evidence supports a role for NTs and neuro-
genesis in development of anxiety disorders and anxiety
symptoms, although certain mediators may exert varying
effects on different anxiety symptoms. Animal models
have demonstrated stress-related changes to neurogenesis
in areas associated with mood and anxiety disorders
including the hippocampus (Cirulli et al. 2010). Expo-
sure to neonatal stress can reduce expression of hippo-
campal BDNF via altering gene expression (Roth et al.
2009; Roth and Sweatt 2011), which may facilitate vul-
nerability to mood and anxiety as consequence of
decreased neuronal survival (Gomez-Pinilla and Vayn-
man 2005). In addition, altered levels of BDNF and their
Trk B receptors may occur in dopaminergic pathways
projecting from the ventral tegmental area in the mid-
brain to the nucleus accumbens (Yu and Chen 2011).
Changes in BDNF appear associated with increased anxi-
ety behaviors. Intrahippocampal injections of BDNF in
rats lead to an increase in anxiety assessed by facilitatory
avoidance and the light–dark test. This was blocked by a
5HT1a antagonist suggesting a modulatory role of sero-
tonin (Casarotto et al. 2012). Social deprivation stress
leads to the development of anxiety in mice, and this
appears to be modulated by reductions in BDNF (Berry
et al. 2012). In a cross-sectional study of a healthy pop-
ulation, plasma BDNF levels were negatively associated
with somatization, obsessive–compulsiveness, interper-
sonal sensitivity, and anxiety (Bhang et al. 2012). BDNF
may also be a modulatory factor in the development of
PTSD (Rakofsky et al. 2012).
Another NT that appears important in anxiety regula-
tion is nerve growth factor (NGF). NGF is increased
under conditions of stress in both animal models and
humans (Aloe et al. 1986, 1994, 2002), and appears to be
important in resilience to stress-related neuropsychiatric
disorders (for review see Alleva and Francia 2009). Inter-
estingly, animal models demonstrate that increases in
release of NGF are most marked under conditions of
stressful behavioral interactions between animals, with
lesser increases seen under physical restraint stress (Aloe
et al. 1986; Branchi et al. 2004; Alleva and Francia 2009).
Further evidence suggests that levels of fibroblast growth
factor 2 (FGF2) in the hippocampus are decreased in
animals with higher anxiety and lower response to novelty
(Perez et al. 2009) and that early life administration of
FGF2 is able to prevent increased anxiety in later life
(Turner et al. 2011).
Maternal exercise can lead to increased expression of
NTs, including VEGF and BDNF, in the PFC of offspring
that is associated with decreased anxiety (Aksu et al.
2012). Exercise also appears able to protect against the
negative effect of maternal deprivation on expression of
these NTs (Uysal et al. 2011).
Cigarette smoking and nicotine in particular appear to
exert effects on expression of NTs, although the literature
is sparse and heterogeneous. For example, cigarette smok-
ing and repeated nicotine exposure has been associated
with decreased expression of BDNF in animal models
(Yeom et al. 2005; Tuon et al. 2010). In addition, plasma
levels of BDNF are significantly lower in smokers than
nonsmokers in human studies, with levels increasing with
greater duration of smoking abstinence (Kim et al. 2007;
Bhang et al. 2010). However, other results have suggested
that nicotine exerts a positive effect on BDNF levels. For
example, nicotine administration has been associated with
increased levels of BDNF and FGF-2 in animal striatum
(Maggio et al. 1997). The neurotrophic augmenting
effects of nicotine in this situation is hypothesized to
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underpin a therapeutic benefit of cholinergic stimulation
on Parkinson’s disease by protecting dopaminergic
neurons from damage. In a further study, traumatic brain
injury revealed a positive effect of chronic cigarette smok-
ing on BDNF expression (Lee et al. 2012). Nicotine expo-
sure has also been associated with significant increases in
NGF (French et al. 1999; Hernandez and Terry 2005) in
the hippocampus and with transient decreases in NT-3
(French et al. 1999), although once again results are not
consistent which may relate to differences in nicotine
administration (Hernandez and Terry 2005).
Differences in NT expression in response to cigarette
smoking are likely dependent upon numerous factors,
including the relative roles of nicotine and other compo-
nents of cigarette smoke (e.g., free radicals) and the devel-
opmental stage at which exposure occurs. Given the key
role of NTs in brain neurodevelopment, distortion to dif-
ferent NTs in early development may facilitate disordered
growth in brain architecture (Abreu-Villaca et al. 2003a;
DeBry and Tiffany 2008). Such effects may leave the over-
all system more vulnerable to disorders such as increased
anxiety. If exposure occurs later, alterations to NTs may
undermine normal compensatory and protective mecha-
nisms available to neuronal cells, leaving cells at greater
risk of damage or induced apoptosis. Future studies
should evaluate the roles of nicotine and other constitu-
ents of cigarette smoke on the levels of NTs correlated
with anxiety and depressive behaviors in animal models,
taking into account the different stages of development at
which exposure can occur.
Epigenetic effects
The study of epigenetic changes in anxiety disorders is a
relatively new field, although some preliminary evidence
suggests that cigarette smoke may lead to changes in gene
expression predisposing to increased anxiety. For exam-
ple, smoking has been associated with epigenetic regula-
tion of MAO-B via a reduction in methylation of its gene
promoter. This change leads to increased production of
MAO-B persisting long after smoking is ceased (Launay
et al. 2009) that can alter neurotransmitter concentra-
tions. In addition, prenatal exposure to environmental
tobacco smoke has been demonstrated to modify expres-
sion of genes controlling key functions such as synaptic
function, neurogenesis, axonal growth, and cellular sur-
vival in the developing hippocampus (Mukhopadhyay
et al. 2010). Data from cardiovascular research have also
demonstrated the potential of gestational cigarette smoke
exposure to upregulate expression of genes associated
with production of proinflammatory substances in devel-
oping primates, which may increase vulnerability to vas-
cular disease in later life (Villablanca et al. 2010). In
depression, preliminary research has identified interrela-
tionships between levels of gene methylation and inflam-
matory mediators that may contribute to pathogenesis via
alteration of tryptophan metabolism (Uddin et al. 2011).
Investigation of epigenetic changes may provide insights
into how cigarette smoking can impact gene expression in
potentially contributing to pathogenesis of anxiety disor-
ders, although empirical data are currently very limited.
One potential genetic influence that could be explored is
the role of prototoxin gene LYNX2. LYNX2 encodes for
proteins that modulate activity of neuronal nAChRs, the
neural target of smoking-ingested nicotine. LYNX2-
encoded proteins modify nAChR receptor control of
glutamate release from the medial PFC. Loss of LYNX2
was associated with increased glutamatergic activity and
increased anxiety behaviors in one study, suggesting a
possible role in controlling anxiety responses (Tekinay
et al. 2009). Further studies are required to assess whether
LYNX2 functioning may affect the alterations to nAChRs
provoked by prolonged nicotine exposure in smokers.
The above findings (summarized in Fig. 1) suggest a
potential role for inflammation, O&NS, mitochondria,
NTs, and epigenetic alterations in the pathogenesis of
anxiety disorders, although further investigation is
required to delineate these relationships. Cigarette smok-
ing can modulate all of these pathways, potentially
distorting cellular functioning and neuronal architecture
predisposing to higher vulnerability to developing anxiety
disorders.
Cigarette Smoke Exposure, Nicotine,
and Altered Neurodevelopment:
Increasing the Risk of Anxiety
Disorders?
Cigarette smoke is known to be deleterious to neurode-
velopment (Picciotto et al. 2002; Slotkin 2004; Slikker
et al. 2005; DeBry and Tiffany 2008), and exposure to
cigarette smoke in early neurodevelopment appears to
increase the risk of developing anxiety in later life (Bandi-
era et al. 2011; Jamal et al. 2011). During early neurode-
velopment, cigarette exposure can be direct (e.g., early
adolescent smoking, in utero exposure to maternal smok-
ing), or second hand as environmental smoke exposure
(Bandiera et al. 2011). Given the diversity of active com-
pounds in cigarette smoke, we focus here primarily on
the specific influence of nicotine (Newman et al. 2002a)
on neurodevelopment. However, as cigarette smoke con-
tains many substances that either directly (e.g., free radi-
cals) or indirectly (e.g., metals) exert effects on O&NS
stress pathways, immune and mitochondrial functions, it
is possible these effects also influence neurodevelopment
and potentially subsequent anxiety risk.
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Nicotine readily crosses the placenta and enters the
fetal blood stream in utero (Lambers and Clark 1996).
Exposure in utero has also been associated with later
behavioral and social problems (Nicoll-Griffith et al.
2001; Piquero et al. 2002; Brion et al. 2010), suggesting
the potential to alter neurodevelopmental trajectories.
Nicotine’s action as a specific agonist of nAChRs is facili-
tated by the very early expression (prior to neurulation)
of these receptors in the developing CNS (Atluri et al.
2001; Schneider et al. 2002). Cholinergic inputs are criti-
cal during brain development, underwriting many key
processes including axonal and synaptic growth, promot-
ing neurogenesis, facilitating planned apoptosis, and
initiating the switch between neuronal replication and dif-
ferentiation (Slotkin 2004). Increasing evidence suggests
nicotine agonism of nAChRs may exert deleterious neuro-
developmental effects. Given the rapid rate of neurodevel-
opment in utero, deleterious effects will likely be most
significant during this time, but might continue to occur
at any time when there is significant development
(e.g., during adolescence) (DeBry and Tiffany 2008).
Agonism of nAChRs by nicotine is more prolonged
than that exerted by acetylcholine in normal cholinergic
transmission due to differences in concentration and
clearance. Nicotine presented in utero is usually present
in higher concentrations, and is more slowly cleared, than
endogenous acetylcholine (DeBry and Tiffany 2008). As
consequence, nicotine can induce enhanced nAChR acti-
vation, facilitating adaptive effects such as receptor
desensitization, and if excessive, direct toxicity (DeBry
and Tiffany 2008). These “neuroteratogenic” effects occur
at doses well below that required for growth impairment.
Figure 1. Multiple pathways that are associated with development of anxiety disorders are affected by cigarette smoke and nicotine, including
diverse neurotransmitter systems, inflammation and the immune system, oxidative and nitrosative stress, neurotrophins and neurogenesis,
mitochondrial function, and epigenetic influences. It is possible these pathways may underpin how exposure to cigarette smoke could increase
anxiety symptoms and expression of anxiety disorders. 5-HT, 5-hydroxytryptophan; BDNF, brain-derived neurotrophic factor; CAT, catalase; CMI,
cell-mediated immune; DA, dopaminergic; DRN, dorsal raphe nucleus; FGF2, fibroblast growth factor 2; GPX, glutathione peroxidase; GSR,
glutathione reductase; IFN-c, interferon-gamma; IL-1, interleukin 1; IL-1RA, interleukin 1 receptor antagonist; IL-10, interleukin-10; IL-12,
interleukin-12; IL-6, interleukin 6; MAO, monoamine oxidase; MDA, malondialdehyde; NA, noradrenergic; NGF, nerve growth factor; O&NS,
oxidative and nitrosative stress; PICs, proinflammatory cytokines; SOD, superoxide dismutase; SSRI, selective serotonin reuptake inhibitor; TBARS,
thiobarbituric acid reactive substances; TNF-a, tumor necrosis factor-alpha; TRYCATs, tryptophan catabolit.
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Animal models have demonstrated that nicotine exposure
leads to quite profound distortion of early neural devel-
opment characterized by increased apoptosis and enlarge-
ment of intercellular spaces (Roy et al. 1998). Even
though substantial recovery appears to occur such that
brains with grossly distorted architecture in utero do not
appear grossly abnormal in adolescence or adulthood,
there remain long-lasting effects of nicotine exposure to
neuronal architecture, cellular functioning and survival,
and DNA expression and regulation. For example, prena-
tal nicotine exposure has been associated with persisting
alterations in cellular architecture in the hippocampus
(Roy et al. 2002; Abdel-Rahman et al. 2005; Oliveira-
da-Silva et al. 2009) and somatosensory cortex (Roy and
Sabherwal 1994), decreased DNA expression in brainstem,
forebrain, and cerebellum (McFarland et al. 1991), persis-
tently enhanced markers of cellular damage and apoptosis
(e.g., c-fos and ornithine decarboxylase; Slotkin et al.
1991; Trauth et al. 1999). Many effects have demonstrated
persistence into adolescence. For example, decreased syn-
aptic activity in noradrenergic and dopaminergic neurons
evident in the early postnatal period of rats exposed to
nicotine prenatally has been demonstrated to reemerge
with pubertal onset (Navarro et al. 1988), either as
reduced activity or as reduced responsiveness to normal
cholinergic stimulation (Seidler et al. 1992). Prenatal
exposure to nicotine also causes ongoing alteration to
nAChRs that extend in adolescence (Gold et al. 2009). In
addition, genetic profiling studies have revealed that ado-
lescent genes coding for the ventral tegmental area, some
of which encode for neurite development, psychological
disorders, development disorders, and nervous system
development, appear more vulnerable to long-term effects
of chronic nicotine exposure than adult genes (Doura
et al. 2010).
Evidence supports that exposure to nicotine prenatally
and during early postnatal life leads to increased anxio-
genic behaviors in rats (Eppolito et al. 2010). Interest-
ingly, measures of increased anxiety behavior in the
Elevated Plus Maze in those rats exposed to prenatal nico-
tine were present in adulthood but not in adolescence,
and although the result was more prominent in female
rats, males also demonstrated the response (Eppolito
et al. 2010). The exposure to nicotine before and shortly
after birth was associated with impairment to fear extinc-
tion (Eppolito et al. 2010), which replicated results from
chronic nicotine exposure in adolescence but not adult-
hood (Smith et al. 2006). This may suggest that exposure
to nicotine in high-activity neurodevelopmental periods
may exert more deleterious effects than in adulthood. It
is possible that chronic administration of nicotine, via
altered nAChR activity, may influence gene expression
and plasticity in the medial PFC and amygdala (Brown
and Kolb 2001; Li et al. 2004; Polesskaya et al. 2007).
This interaction may underpin the lack of extinction
learning displayed in rats that are exposed to chronic
nicotine (Eppolito et al. 2010).
Nicotine induces production of oxidative stress markers
and reduces antioxidant defenses, contributing a major
proportion of the net oxidative stress from cigarette use
(Bhagwat et al. 1998; Yildiz et al. 1998; Guan et al. 2003;
Qiao et al. 2005; Das et al. 2009), although nicotine is
known exhibit both pro- and antioxidant effects (Li et al.
2000; Tizabi et al. 2003). Nicotine increases lipid peroxi-
dation markers that can be prevented by coadministration
of free radical scavenger vitamin E (Qiao et al. 2005) and
has demonstrated antimitotic properties (Qiao et al.
2003). Increased production of O&NS, and antimitotic
properties, has been demonstrated during cell differentia-
tion (in association with increased in nAChR density)
(Qiao et al. 2003, 2005). It is possible that the balance
between damaging and protective effects of nicotine may
depend upon the degree of stimulated oxidative stress – a
small amount of oxidative stress could have positive
effects in stimulating normal cellular processes, but signif-
icantly increased oxidative stress could overwhelm protec-
tive mechanisms leading to direct cellular damage
(Newman et al. 2002a).
Given the increased level of O&NS present in adoles-
cence, it could be hypothesized that vulnerability to toxic
effects of nicotine-induced oxidative stress would be
heightened (Qiao et al. 2005). Nicotine has demonstrated
adverse neurobiological effects during adolescence, with
these effects seemingly dependent on only early small and
infrequent exposure to nicotine (Abreu-Villaca et al.
2003b). In keeping with this hypothesis, administration of
nicotine for 1 week to adolescent rats resulted in a signifi-
cant increase in TBARS with effects that would have been
observed at low levels of exposure (Qiao et al. 2005).
Other mechanisms of nicotine-induced damage may
include upregulation of mRNA expression encoding pro-
teins associated with cell death and cell differentiation.
For example, increased levels of such proteins (p53) and
reduction of DNA were found in the hippocampus, cor-
tex, and midbrain in adolescent rats (Trauth et al. 2000).
These effects were not of the same magnitude as those
seen with nicotine exposure in utero (Levin and Slotkin
1998).
Nicotine also exerts effects on numerous trophic factors
(DeBry and Tiffany 2008; Son and Winzer-Serhan 2009),
including upregulation of FGF (Belluardo et al. 2004),
PDGF (platelet-derived growth factor), BDNF (Kenny
et al. 2000), Trk A (Formaggio et al. 2010), and NGF. It
is possible that exacerbated expression of these growth-
supporting factors via nicotine’s agonism of nAChRs may
interfere with normal neurodevelopmental processes. As
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nicotine’s stimulation of nAChRs is potentially more pro-
longed than normal cholinergic transmission, expression
of NTs may be higher than required for normal neuro-
development, with this higher expression leading to
disordered development of neuronal architecture (Abreu-
Villaca et al. 2003c). Such effects may predispose an
increased risk of developing anxiety and other psychiatric
disorders in later life.
Therapeutic Implications for Anxiety
Disorders
A number of these insights may have treatment implica-
tions for anxiety-based disorders and symptoms. It is
hypothesized that adaptation and desensitization of
nAChRs may underpin the effect of cigarettes on anxiety
and mood regulation (Mineur and Picciotto 2010), based
on the association between higher smoking rates and
mood dysregulation (e.g., depression) (Covey et al.
1998), animal models demonstrating antidepressant
effects of acute nicotine on learned helplessness (Semba
et al. 1998) and other depression behaviors (Djuric et al.
1999; Tizabi et al. 1999), the effect of antidepressants
such as bupropion as smoking cessation aids (Hurt et al.
1997) and that some antidepressants also serve as non-
competitive inhibitors of nAChRs (Shytle et al. 2002).
Many of these effects apply to increased anxiety, suggest-
ing that certain central nAChRs may serve as a new
potential treatment target.
Numerous studies have demonstrated potential for use
of centrally acting nAChR antagonists in anxiety treatment.
For example, the nAChR antagonist mecamylamine has
produced anxiolytic improvement in multiple animal
models (Newman et al. 2002b). Mecamylamine was dem-
onstrated to be a useful augmentation agent to SSRI treat-
ment of major depression (George et al. 2008), and
administration of mecamylamine also appears capable of
blocking dexamethasone-induced anxiety, which occurs
concurrently with upregulation of BDNF levels (Park et al.
2011). The anxiolytic effects of nAChR antagonism have
also been confirmed using an alternative agent, lobeline
(Roni and Rahman 2011). Human data on the use of
nAChR antagonist for anxiety are scarce. A possible insight
comes from the use of bupropion, which blocks reuptake
of noradrenaline and dopamine but in addition exerts a
noncompetitive antagonist effect at several subtypes of
nAChRs (Arias 2009). Bupropion has demonstrated signifi-
cant anxiolytic effects equivalent to the action of SSRIs in
treatment of patients with major depressive disorder, and
this effect on nAChRs may underpin part of this effect,
although other explanations are possible (e.g., effect on
noradrenergic and dopaminergic systems) (Papakostas
et al. 2008). Future randomized studies will provide insight
into therapeutic possibilities exploiting modification of
nAChRs in treating anxiety disorders.
Other potential agents worthy of consideration include
agents that can guard against inflammatory- and O&NS-
mediated effects. For example, the tetracyclic antibiotic mi-
nocycline, which exerts strong anti-inflammatory effects,
has been shown to potentially modulate anxiety behaviors
after cardiac arrest (Neigh et al. 2009). In addition, inhibi-
tion of COX2 has been shown in animal models to prevent
anxiety development (Casolini et al. 2002), and celecoxib,
a COX-2 inhibitor, has shown benefit as an augmentation
agent to SSRIs in depression (Muller et al. 2006). Antioxi-
dant treatments, such as n-acetylcysteine, have shown some
promise in augmentation of treatment in mood disorders
(Berk et al. 2012), and exploration of their utility in anxi-
ety disorders would be of use.
Further research exploring the effects of agents that
influence the identified pathways may provide important
new avenues for therapy for pathological anxiety. In addi-
tion, such work will be important in further understand-
ing the biological pathways facilitating development and
reinforcement of cigarette smoking. These efforts may
assist the development of more advanced treatments for
smoking cessation, particularly in patients with anxiety
disorders who exhibit poor rates of success to traditional
cessation strategies (Piper et al. 2011).
Limitations and Directions for Future
Research
A number of interpretational caveats must be considered
when considering the evidence presented. First, the litera-
ture discussed above is drawn from a variety of sources,
utilizing differing measures of anxiety (e.g., different diag-
nostic measures for individual anxiety disorders, different
symptoms scale measures of anxiety or psychological
stress, different animal anxiety models) and different rates
of smoking or nicotine exposure. Studies also employed
various confounders and other study designs which make
cross-comparisons difficult. Where possible, we have
discussed individual anxiety disorder diagnoses noting the
significant distinctions between different disorder groups.
In particular, evidence suggests that different anxiety dis-
order subtypes display significantly different rates of smok-
ing (Kalman et al. 2005). However, the scant literature
available for some pathways prevented an analysis by dis-
order subtype, with most evidence on potential pathway
effects drawn from cross-sectional investigations of animal
models. The cross-sectional nature of this literature
impeded conclusions regarding causation, and it is possi-
ble that observations highlighted (e.g., smoking with
changes to brain volume) may be unidirectional, bidirec-
tional, or mediated by other shared factors. In addition,
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there currently exists a paucity of research assessing a par-
ticular pathway in concert with smoking and anxiety. Few
prospective data are available assessing the impact of
changes to specific systems on anxiety symptoms in
response to cigarette smoking. In addition, aside from the
inherent difficulties in translating animal model data to
humans, many of the above associations displayed vari-
ability in results depending upon study variables, including
animal model used or experimental design. In addition,
much of the literature has focused solely on the role of
nicotine and not the other known toxic ingredients of cig-
arette smoke including free radicals and metals. There was
also significant variability in expression and function of
these systems between different groups (e.g., men vs.
women) and individuals within these groups, and hence
much further work is required to ascertain how these
influences draw together. Understanding reasons under-
pinning differential expression between groups may help
clarify further key elements to anxiety development.
Women, for example, are known to exhibit higher rates of
anxiety disorders, which likely relates to a combination of
biological (e.g., different hormonal compositions) and psy-
chological factors, and hence further analysis of these
effects on the described pathways may prove enlightening.
The acute and long-term effects of any agent that causes a
robust homeostatic adaptation are often quite different;
this needs to be taken into account in interpretation of
acute data, and in extrapolating to management strategies.
Future research efforts in this area should attempt to
address some of these challenges. First, it would be useful
to ascertain the effects of nicotine versus other cigarette
constituents to the above pathways in humans. The use
of populations with high consumption of Snus, such as
Norway, presents as opportunity for such analyses to be
conducted prospectively, and combined with follow-up
behavioral assessments, serum analysis of relevant markers
(e.g., inflammatory or O&NS), assessment of genetic
function, and functional and structural imaging. Such
studies could be extended over time to investigate specific
changes between different anxiety disorders (e.g., PD,
GAD, PTSD), different subsets of the population (e.g.,
cultural or gender groups), and in individuals with other
risk elements known to influence these similar pathways
(e.g., history of childhood trauma, comorbid medical ill-
ness). It is likely that interindividual differences in genet-
ics and epigenetic alterations will also complicate these
effects, and as such further exploration of this evolving
area will be of foremost importance. Given that effects on
multiple pathways may exert incremental increases in risk
for developing anxiety, triangulation of potential effects
involving a combination of animal and human models
will likely be required as power to detect small effects will
only be found in very large studies.
Conclusion
Many studies have suggested that cigarette smoking may
increase the risk of developing increased anxiety, although
confirmation of this causality is yet to be confirmed. Evi-
dence into pathogenesis of anxiety disorders and
increased anxiety symptoms potentially supports a role
for diverse neurotransmitter systems, the immune system,
O&NS, mitochondrial function, and epigenetic regulation,
although the literature is heterogeneous and scant in cer-
tain areas. Ingredients that are present in cigarette smoke,
including nicotine and other toxic chemicals, exert influ-
ences on all of these pathways. These effects may at least
partially underpin the biological mechanisms through
which smoking may contribute to increased anxiety, and
potentially serve as a useful framework for further
research efforts. Similar pathways are likely to be opera-
tive in other states characterized by fight, flight, freeze
responses such as anger, mood disorders (e.g., depressive
states), and psychotic disorders. The exposure to nicotine
and other cigarette ingredients may also exert neurodevel-
opment influences capable of changing anxiety trajecto-
ries, underscoring the importance of reducing exposure to
cigarette during gestation and throughout childhood.
Centrally, nAChRs appear to be a crucial mediator of the
anxiety-modifying effects of cigarette smoke and may rep-
resent a future therapeutic target for anxiety disorders. In
addition, anti-inflammatory and antioxidant agents may
assist in improving anxiety symptoms, as they may do in
depression. Further studies addressing this area may elicit
insights into new therapeutic opportunities.
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